ArticlePathogens (Basel, Switzerland)2022
Severe West Nile Virus Neuroinvasive Disease: Clinical Characteristics, Short- and Long-Term Outcomes.
Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 40 citations in OpenAlex.
- Rehabilitation approaches in West Nile Virus survivors: a systematic review.European journal of physical and rehabilitation medicine · 2024Pooled it
- Usutu virus promotes West Nile virus replication in Culex pipiens biotype molestus during simultaneous and sequential co-infections.PLoS pathogens · 2026Article
- Impact of metabolic comorbidities on the clinical course of West Nile virus infection.Journal of endocrinological investigation · 2026Article
- Acute Flaccid Paralysis Followed by Guillain-Barré Syndrome in West Nile Virus Infection: A Case Report.Cureus · 2026Article
- Spatiotemporal and Demographic Patterns of West Nile Neuroinvasive Disease in Vojvodina, Serbia, 2012-2025.Viruses · 2026Article
- Pharmaceutical Strategies for West Nile Virus in Europe, an Underrecognized Cause of Severe Disease and Mortality in Older Adults: From Supportive Care to Antiviral Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Preexisting yellow fever virus and West Nile virus immunity and pregnancy outcomes in a Nigerian cohort with endemic orthoflavivirus exposure.Emerging microbes & infections · 2025Article
- The Role of TLR3 rs3775291 Variant in West Nile Virus Infection: A Case-Control Study.Microorganisms · 2025Article
- Neuropsychiatric lupus or West Nile encephalitis? Diagnostic dilemmas in two SLE patients and literature review.Internal and emergency medicine · 2025Review
- West Nile Virus Neuroinvasive Disease in Patients Treated With Anti-CD20 Therapies.Neurology. Clinical practice · 2025Article
- Zoonotic Orthoflaviviruses Related to Birds: A Literature Review.Microorganisms · 2025Review
- [Climate change and vector-borne disease-significance for intensive care and emergency medicine].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Review
- Clinical Characteristics, Laboratory Parameters, and Molecular Epidemiology of Neuroinvasive Flavivirus Infections in a Hotspot Region of Eastern Croatia.Pathogens (Basel, Switzerland) · 2025Article
- West Nile Virus (PeerJ · 2025Article
- Factors contributing to mosquito-borne disease: A systematic review in the Middle East and North Africa (MENA) region.Current research in parasitology & vector-borne diseases · 2025Review
- Clinical and Diagnostic Features of West Nile Virus Neuroinvasive Disease in New York City.Pathogens (Basel, Switzerland) · 2024Article
- Proinflammatory Chemokine Levels in Cerebrospinal Fluid of Patients with Neuroinvasive Flavivirus Infections.Microorganisms · 2024Article
- Neurological and neuromuscular manifestations in patients with West Nile neuroinvasive disease, Belgrade area, Serbia, season 2022.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- A chimeric vaccine protects farmed saltwater crocodiles from West Nile virus-induced skin lesions.NPJ vaccines · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 7 institutions in 2 countries.
Funding
Abstract
West Nile Virus Neuroinvasive Disease (WNV NID) requires prolonged intensive care treatment, resulting in high mortality and early disability. Long-term results are lacking. We have conducted an observational retrospective study with a prospective follow-up of WNV NID patients treated at the Intensive Care Unit (ICU), University Hospital for Infectious Diseases, Zagreb, Croatia, 2013-2018. Short-term outcomes were vital status, length of stay (LOS), modified Rankin Scale (mRS), and disposition at discharge. Long-term outcomes were vital status and mRS at follow-up. Twenty-three patients were identified, 78.3% males, median age 72 (range 33-84) years. Two patients (8.7%) died in the ICU, with no lethal outcomes after ICU discharge. The median ICU LOS was 19 days (range 5-73), and the median hospital LOS was 34 days (range 7-97). At discharge, 15 (65.2%) patients had moderate to severe/mRS 3-5, 6 (26.0%) had slight disability/mRS 2-1, no patients were symptom-free/mRS 0. Ten (47.6%) survivors were discharged to rehabilitation facilities. The median time to follow-up was nine months (range 6-69). At follow-up, seven patients died (30.5%), five (21.7%) had moderate to severe/mRS 3-5, one (4.3%) had slight disability/mRS 2-1, six (26.1%) had no symptoms/mRS 0, and four (17.4%) were lost to follow-up. Briefly, ten (43.5%) survivors improved their functional status, one (4.3%) was unaltered, and one (4.3%) aggravated. In patients with severe WNV NID, intensive treatment in the acute phase followed by inpatient rehabilitation resulted in significant recovery of functional status after several months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.